This page is a permanent link to the reply below and its nested replies. See all post replies »
Khenpal1 · M
We're looking at months, maybe a year, before we have a roll out of a safe and effective vaccine that will provide us with the required 80% take-up to clear the virus from the population.The Pfizer vaccine needs to be stored at minus 70 degrees Celsius- — much colder than what most medicines and vaccines require.The prospect of building a cold chain infrastructure poses new challenges. While research labs and hospitals affiliated with research institutions often have these ultra-cold freezers, many community hospitals and clinics do not.
Khenpal1 · M
@helenS ultra-freezers- large freezers, at $10,000 apiece, that can each store about 30,000 doses of vaccines at temperatures as cold as minus 80 degrees Celsius. Smaller portable freezers, which cost roughly $8,000 each, that will be used to transport doses from one location to another.The portable freezers can potentially store up to 12,000 doses each. The freezers can accommodate a range of temperatures. So if it turns out they won’t need to store vaccines at that low of a temperature, they could also store, for example, the Moderna vaccine, which must be kept at minus 20 degrees Celsius.The portable freezers may also be used as mobile or “pop-up” vaccination units, similar to the mobile testing units that health care providers and local health departments have set up for diagnostic testing for the virus. It will cost billions just for the freezers alone. Then it takes two shots and 30 days to it to work.
Khenpal1 · M
@Khenpal1 And that is all dependent upon the following;
1. Further testing to show it is effective and safe for the over 55s.
2. Further testing to establish whether it is safe to use on cancer patients or others with reduced immune responses.
3. Peer review.
4. Safety data being released for scrutiny.
5. Production and distribution time.
1. Further testing to show it is effective and safe for the over 55s.
2. Further testing to establish whether it is safe to use on cancer patients or others with reduced immune responses.
3. Peer review.
4. Safety data being released for scrutiny.
5. Production and distribution time.